Skip to main content

Table 3 Primary outcomes

From: In vitro fertilisation with recombinant follicle stimulating hormone requires less IU usage compared with highly purified human menopausal gonadotrophin: results from a European retrospective observational chart review

Characteristic rFSH hMG-HP p-value* All Patients
Mean (SD) total dose of gonadotrophin per IVF cycle (IU) (All patients) 2072.53 (768.73) 2540.14 (883.08) <0.01 2194.13 (825.9)
   (≤35 years) 1974.90 (726.77) 2418.56 (834.46) <0.01 2085.84 (779.18)
   (≥36 years) 2280.41 (813.09) 2761.60 (925.33) <0.01 2415.36 (873.21)
Mean (SD) total days of gonadotrophin treatment per IVF cycle (All patients) 11.41 (2.24) 11.65 (2.42) <0.01 11.47 (2.29)
   (≤35 years) 11.41 (2.28) 11.65 (2.48) <0.01 11.47 (2.33)
   (≥36 years) 11.41 (2.16) 11.65 (2.31) <0.01 11.48 (2.21)
Mean (SD) starting dose of gonadotrophin (IU) (All patients) 176.38 (50.01) 206.16 (55.64) <0.01 184.12 (53.16)
   (≤35 years) 167.97 (46.65) 195.94 (53.48) <0.01 174.97 (49.94)
   (≥36 years) 194.26 (52.18) 224.76 (54.67) <0.01 202.82 (54.63)
Median starting dose of gonadotrophin (IU) (All patients) 150 225 <0.01 150
   (≤35 years) 150 225 <0.01 150
   (≥36 years) 187.5 225 <0.01 225
  1. * Statistical significance for all outcomes assessed via Wilcoxon two sample test and two sample T-test